IN THE UNITED STATES DISTRICT COURT

FOR THE DISTRICT OF HAWAII

ABBVIE INC. (a Delaware corporation); ALLERGAN, INC. (a Delaware corporation); DURATA THERAPEUTICS, INC. (a Delaware corporation); ABBVIE PRODUCTS LLC (a Georgia limited liability company); PHARMACYCLICS LLC (a Delaware limited liability company); ALLERGAN SALES, LLC (a Delaware limited liability company), Plaintiffs, vs. ANNE E. LOPEZ, in her official capacity as ATTORNEY GENERAL OF THE STATE OF HAWAI'I, Defendant.	CIVIL NO. 25-00230 SASP-WRP ORDER GRANTING PLAINTIFFS' MOTION FOR LEAVE TO FILE DOCUMENTS UNDER SEAL

ORDER GRANTING PLAINTIFFS' MOTION FOR LEAVE TO FILE DOCUMENTS UNDER SEAL

Before the Court is Plaintiffs AbbVie Inc., Allergan Sales, LLC, Allergan, Inc., Durata Therapeutics, Inc., and Pharmacyclics LLC's (collectively "AbbVie") Motion for Leave to File Documents Under Seal ("Motion"), ECF No. 166, which seeks to have (1) Exhibits 7 through 21 in support of AbbVie's trial brief, and (2) an unredacted version of AbbVie's trial brief filed under seal. All but one of the exhibits sought to be sealed was designated "Confidential" or

"Attorneys Eyes Only" by non-parties. And AbbVie's trial brief quotes or paraphrases material from those exhibits. Pursuant to their designation of these materials as "Confidential" and/or "Confidential – Attorneys' Eyes Only" pursuant to the Amended Stipulated Protective Order, ECF No. 108, the non-parties affirmed that the information contained therein is non-public and commercially sensitive, contains trade secrets, and/or is likely to cause harm if disclosed publicly.

Upon consideration of AbbVie's Motion, and having reviewed the proposed sealed exhibits, the Court FINDS that compelling reasons exist to seal:

(1) Three exhibits obtained via third-party discovery from Queen's Medical Center ("QMC"), including excerpts from the transcript of the March 3, 2026 Rule 30(b)(6) deposition of QMC; and contracts between QMC and various contract pharmacies.

(2) Seven exhibits obtained via third-party discovery from Castle Medical Center ("CMC"), including excerpts from the transcript of the September 11, 2026 Rule 30(b)(6) deposition of CMC; contracts between CMC and various contract pharmacies; and CMC's 340B contract pharmacy policy.

(3) Three exhibits obtained via third-party discovery from Hawai'i Pacific Health ("HPH"), including excerpts from the transcript of

the April 28, 2026 Rule 30(b)(6) deposition of Jennifer Dacumos and contracts between HPH and contract pharmacies.

(4) One exhibit obtained via third-party discovery from Verity Solutions Group ("Verity") representing an excerpt from the transcript of the December 8, 2026 Rule 30(b)(6) deposition of Verity.

(5) One exhibit of sensitive commercial information of AbbVie, Inc., a chart representing the number of 340B discounts AbbVie has provided in Hawai'i. This chart contains and is the product of commercially sensitive and proprietary business information, including confidential sales data, the identities of entities purchasing drugs, the type of products sold and shipped to a particular pharmacy, quantities of products sold, where those products were shipped, financial information affiliated with the transactions, and more. Such information, if made public, would negatively impact AbbVie's business and competitive position.

(6) Two expert reports citing material designated confidential under the Amended Stipulated Protective Order in this case, ECF No. 108.

(7) AbbVie's Trial Brief, which includes citations and quotations from the above-listed material, which has been designated confidential under the Amended Stipulated Protective Order in this case, ECF No. 108.

(8) The Court finds that AbbVie's proposed sealing is narrowly tailored to allow the judicial record in this case to be as open as possible to the public. AbbVie seeks only to seal exhibits that contain information designated "Confidential" or "Attorneys Eyes Only." And AbbVie shall file a redacted copy of its trial brief so as to allow public access to its arguments. Sealing exhibits filed on the Court's public docket, too, does not foreclose other approaches to disclosure of that material that the Court may elect at trial.

For these reasons, the Motion, ECF No. 166, is hereby GRANTED. Accordingly, AbbVie is authorized to file under seal the exhibits identified in the subject Motion.

The Court nonetheless notes that pursuant to the Amended Stipulated Protective Order issued on April 16, 2026, ECF No. 108, effected non-parties have fourteen (14) days from the date the Motion was served, to file their respective

positions regarding the Motion. Further, should any party or non-party timely oppose AbbVie's Motion, the Court shall set a hearing on the matter.

IT IS SO ORDERED.

DATED: Honolulu, Hawai'i, October13, 2026.

Shanlyn A.S. Park
United States District Judge